Vireo Growth (VREOF) Gains from Investment Securities (2024 - 2026)
Vireo Growth (VREOF) posted Gains from Investment Securities of $5.5 million for Q1 2026, up 1664.33% sequentially from -$351588.0 in Q4 2025, and up 1000.0% YoY from $500000.0 in Q1 2025.
Vireo Growth (VREOF) Gains from Investment Securities (2024 - 2026) Analysis & Trends
Vireo Growth has reported Gains from Investment Securities for 3 years, with the latest figure at $5.5 million in Q1 2026.
- Quarterly Gains from Investment Securities rose 1000.0% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (up 273.85% YoY) and the FY2025 annual result came in at $586273.0, up 275.73% from the prior year.
- Gains from Investment Securities grew to $5.5 million in Q1 2026 per VREOF's latest filing, from -$351588.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $5.5 million in Q1 2026 and troughed at -$1.6 million in Q2 2024.
- A 3-year average of $639184.6 and a median of -$60663.0 in 2025 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities slumped 111.91% in 2025, then soared 1000.0% in 2026.
- Over 3 years, Gains from Investment Securities stood at $3.0 million in 2024, then tumbled by 111.91% to -$351588.0 in 2025, then soared by 1664.33% to $5.5 million in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $5.5 million, -$351588.0, and -$60663.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Vireo Growth | 492.80 Mn | 350.50 Mn | 95.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.50 Mn |
| Mar 31, 2026 | 5.50 Mn |
| Dec 31, 2025 | -351,588.00 |
| Dec 31, 2025 | -351,588.00 |
| Sep 30, 2025 | -60,663.00 |
| Sep 30, 2025 | -60,663.00 |
| Jun 30, 2025 | 498,524.00 |
| Jun 30, 2025 | 498,524.00 |
| Mar 31, 2025 | 500,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 2.95 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Sep 30, 2024 | -354,328.00 |
| Sep 30, 2024 | -354,328.00 |
| Jun 30, 2024 | -1.60 Mn |
| Jun 30, 2024 | -1.60 Mn |
| Mar 31, 2024 | -1.33 Mn |
| Mar 31, 2024 | -1.33 Mn |